Physician profile
Cornelius Clancy
NPI 1326075094
$93,482.48
in general payments reported to CMS, 2019-2025
9 companies · $3,034 in 2025
The $3,034 reported for 2025 was more than what 88% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $7,250 · 2021: $6,105 · 2022: $19K · 2023: $5,609 · 2024: $13K · 2025: $3,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,562 · Consulting Fee: $8,256 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,700 · Honoraria: $750 · Food and Beverage: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,561.83 |
| Consulting Fee | $8,255.51 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,700.00 |
| Honoraria | $750.00 |
| Food and Beverage | $270.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $53,508.15 | 2019-2022 | |
| Shionogi INC | $29,878.47 | 2019-2024 | Fetroja |
| La Jolla Pharmaceutical Company | $5,171.27 | 2023-2025 | Xacduro, Zevtera |
| Gilead Sciences, INC. | $3,230.00 | 2024 | Ambisome |
| Meitheal Pharmaceuticals, INC. | $830.19 | 2024 | |
| Melinta Therapeutics, LLC | $743.75 | 2025 | Rezzayo |
| Scynexis, INC. | $92.87 | 2022 | |
| Glaxosmithkline, LLC. | $27.78 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cornelius Clancy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.